BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-38@catalystbrief.girapphe.com
DTSTAMP:20261117T061549Z
LAST-MODIFIED:20261117T061549Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: RayzeBio\, Inc. — RYZ101 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: Study of RYZ101 Compared With SOC i
 n Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed F
 ollowing 177Lu-SSA Therapy.\nSource: https://clinicaltrials.gov/study/NCT0
 5477576\nhttps://catalystbrief.girapphe.com/e/38?lang=en\nNot investment a
 dvice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/38?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
